BridgeBio Pharma, Inc. (BBIO) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2025. BridgeBio Pharma, Inc. is a biopharmaceutical company focused on genetic diseases. The period marks the early commercialization phase of its approved product, Attruby (acoramidis) in the U.S. and Beyonttra in the EU, Japan, and the UK. The company continues to advance late-stage candidates for achondroplasia (infigratinib), ADH1 (encaleret), and LGMD2I/R9 (BBP-418).
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Total Revenues | $110.6 million | $227.2 million | $213.3 million |
| Net Product Revenue | $71.5 million | $108.2 million | $0 |
| License & Services Revenue | $37.4 million | $117.1 million | $213.3 million |
| Net Loss (Common Stockholders) | $(181.9 million) | $(349.3 million) | $(108.7 million) |
| Net Loss Per Share (Diluted) | $(0.95) | $(1.84) | $(0.59) |
| Operating Cash Flow | — | $(279.9 million) | $(144.8 million) |
| Cash & Equivalents (End of Period) | $749.0 million | $749.0 million | $681.1 million (Dec 31, 2024) |
| Total Debt (Notes) | ~$1.86 billion (Principal) | ~$1.86 billion (Principal) | ~$1.30 billion (Principal) |
Material Changes vs. Prior Period
- Revenue Composition Shift: Total revenue increased 6.5% YTD 2025 vs. 2024, driven by $108.2 million in new net product revenue from Attruby. This was partially offset by a $96.2 million decrease in license revenue, primarily due to the recognition of $202.9 million in upfront fees in 2024 (Bayer and Kyowa Kirin agreements) which were not repeated in 2025.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses surged $110.2 million YTD 2025 compared to 2024, driven by commercial launch investments for Attruby. Research and Development (R&D) expenses decreased $33.0 million YTD 2025, largely due to the deconsolidation of two early-stage affiliates in 2024.
- Debt Restructuring: In February 2025, the company issued $575 million in 2031 Convertible Notes. Proceeds were used to fully repay a $450 million term loan (Amended Financing Agreement), resulting in a $21.2 million loss on extinguishment of debt.
- Royalty Financing: In June 2025, the company entered a Royalty Purchase Agreement, selling certain EU royalty rights for $300 million in cash proceeds.
Guidance, Outlook, and Risks
- Commercial Outlook: Management expects future revenue to be primarily generated from product sales of Attruby and royalties from Beyonttra sales by partners (Bayer and Alexion). The company anticipates continuing operating losses for the next several years.
- Liquidity: As of June 30, 2025, the company held $756.9 million in cash, cash equivalents, and marketable securities. Management expects this to fund operations for at least the next 12 months.
- Key Risks:
- Commercialization Execution: Limited experience in commercializing products; success depends on market acceptance and reimbursement for Attruby/Beyonttra.
- Debt Obligations: Significant debt load (~$1.86 billion in notes) and deferred royalty obligations (~$814 million) create substantial interest expense and future cash outflow requirements.
- Regulatory & Development: Ongoing clinical trials for pipeline candidates (infigratinib, encaleret, BBP-418) carry inherent risks of failure or delay.
Investor Verification Checklist
- Attruby Sales Trajectory: Verify the run-rate of net product revenue ($71.5M in Q2) and assess if it supports the commercialization cost structure.
- Debt Service Capacity: Review the interest expense ($37.6M in Q2) and principal repayment schedules for the 2027, 2029, and 2031 Notes against projected cash flows.
- Royalty Agreement Terms: Examine the caps and triggers in the new $300M Royalty Purchase Agreement and the existing Funding Agreement to understand future royalty payout obligations.
- SG&A Efficiency: Monitor the trend of SG&A expenses as the commercial launch matures to ensure costs do not outpace revenue growth.
- Pipeline Milestones: Track progress on infigratinib (achondroplasia) and encaleret (ADH1) as potential future revenue drivers or partnership opportunities.